Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years | Synapse
February 8, 2026Open Access
Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years
Key Points
To assess the risk of febrile seizures following mRNA COVID-19 vaccination in young children.
Analyzed vaccination data for children aged 2-5 years
Calculated incidence rate ratios for febrile seizures
Focused on the period 0-1 days post-vaccination
Identified a small elevated incidence rate ratio of febrile seizures
Found this increase to be within a short timeframe post-vaccination
Abstract
Among children aged 2-5 years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0-1 days following the mRNA-1273 vaccination.